Menu
Login

Report Library

All Reports
MDS/AML KOL Interview

April 09, 2015

Highlights
  • More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects.
  • Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may benefit. However, the program's results are limited by the heterogeneity of the MDS patient population and sponsor's trial design.
  • Since there is an immune component to some subtypes of MDS, some patients may benefit from immunotherapies, but researchers will need to find appropriate patient sub-populations.
  • HDAC inhibitors may have promise in combination with other agents but have disappointed in single-agent trials.
This KOL interview accompanies our other AML content planned for April 2015. We previously published a KOL interview with a pediatric leukemia specialist and an infographic on the AML drug pipeline. We also plan to publish a full special report on AML Treatments and Pipelines and a special report on AML Diagnostics, in collaboration with MedDeviceTracker. For more information on MedDeviceTracker's diagnostics coverage, please visit the MedDeviceTracker website or contact your BioMedTracker sales representative.

For the full report, please download the PDF version at the top of this page.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Acute Myelogenous Leukemia (AML)
Myelodysplastic Syndrome (MDS)

 Additional Resources: